Has anyone dealt with peptide oxidation and deamidation?

Dr.SurgeonPGH said:

They are two different exemptions from the same federal requirements and they buy different things.

This is where I part company with the consensus forming above. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.

ZaraB_AL said:

My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.

Price comparison for compounded supply across sources I've used:

I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.

Dr.PainCLE said:

A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to.

Compounded semaglutide formulations for compounded supply: some pharmacies add ingredients like B12, L-carnitine, or BPC-157 to their semaglutide preparations. Are these beneficial or marketing gimmicks?

My take: B12 addition has some logic (GLP-1s can deplete B12). L-carnitine evidence is weak. BPC-157 for GI protection is theoretically interesting but unproven. I prefer straight semaglutide with no additives — fewer variables, cleaner data on what's working.

One thing that is still open after MounjBrad’s answer:

What actually distinguishes 503A from 503B, in terms of what each may make and from what starting material?

Reporting back.

The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.